drugset / Trial / NCT02966951

Use of Adipose Tissue Derived Mesenchymal Stem Cells for Knee Osteoarthrosis

NCT02966951 ↗

Phase 1 Unknown 10 enrolled Hanan Jafar
NaSingle-groupOpen-labelTreatment

Summary

Adipose tissue derived Mesenchymal Stem cells (ATMSC) will be injected in patients diagnosed with Knee osteoarthrosis

Timeline

Start
2017-01-17
Primary completion
2021-09
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adipose tissue derived mesenchymal stem cell Cell therapy 5e+07 cells Other

Indications